Immune cells armed with antibody enter trial for Hard-to-Treat cancers
NCT ID NCT07441889
First seen Mar 19, 2026 · Last updated Apr 24, 2026 · Updated 2 times
Summary
This early-phase study tests whether immune cells (white blood cells) coated with a special antibody can safely attack and shrink tumors in people with metastatic breast or prostate cancer that has stopped responding to standard treatments. About 23 participants will receive weekly infusions of these armed cells for five weeks, then every other week for four more doses. The main goal is to check for side effects and see if the treatment helps control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.